Issuer Client News

News & Events

Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum

Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum

FORT LAUDERDALE, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company") announced with profound sadness that Samuel R. Nussbaum, MD, an independent director on the Company’s board of directors, passed away on September 23, 2021. Dr. Nussbaum had proudly served on the Company’s board of directors since 2016, where he was a member of the compensation, and nominating and corporate governance committees.

“Sam served our Board with great commitment. He was an outstanding director, leader, and mentor, as well as a friend to all of us at Motus GI. We will miss him dearly and extend our deepest condolences to the entire Nussbaum family,” commented Tim Moran, Director and Chief Executive Officer at Motus GI.

David Hochman, Chairman of the Board, stated, “We are deeply saddened by the loss of a truly special human being. Sam was a person of the highest qualities, passionately committed to medical innovation and the improvement of healthcare delivery and outcomes. All of his work and interactions were guided by his love of people and passion for living. We were very fortunate to have the benefit of his service on our board of directors for the last five years. We will miss him greatly and his family is in our thoughts and prayers.”

Dr. Nussbaum was a highly accomplished senior executive with extensive medical and business experience across the healthcare and life sciences industries. For more than 16 years, he served as the Executive Vice President, Clinical Health Policy, and Chief Medical Officer of Anthem, Inc., where he was responsible for annual health care expenditures through business units focused on care management, health improvement, and provider network contracting. Most recently, Dr. Nussbaum spent the last five years as an influential strategic consultant for EBG Advisors, the consulting arm for Epstein Becker and Green, where he advised life science companies, health care systems, and provider organizations. Dr. Nussbaum also served as a Senior Advisor to Sandbox Industries, a venture fund, and the Ontario Teachers’ Pension Fund. Dr. Nussbaum earned his BA from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit and connect with the Company on TwitterLinkedIn and Facebook.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989

Primary Logo

Source: Motus GI Holdings, Inc.

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures